Commonwealth of Pennsylvania Public School Empls Retrmt SYS Purchases 23,494 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 287.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,674 shares of the company’s stock after purchasing an additional 23,494 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS owned 0.06% of Immunocore worth $955,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Harbour Investments Inc. increased its holdings in Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after purchasing an additional 388 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after acquiring an additional 572 shares during the period. R Squared Ltd boosted its holdings in Immunocore by 7.4% in the fourth quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after acquiring an additional 606 shares during the last quarter. Leonteq Securities AG bought a new stake in Immunocore in the fourth quarter valued at approximately $30,000. Finally, Orion Porfolio Solutions LLC increased its position in Immunocore by 4.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock valued at $752,000 after purchasing an additional 1,031 shares during the period. Institutional investors own 84.50% of the company’s stock.

Immunocore Trading Up 1.4%

Shares of IMCR stock opened at $34.96 on Friday. The company’s fifty day simple moving average is $30.12 and its two-hundred day simple moving average is $31.29. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -63.56 and a beta of 0.73. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $27.56 and a 1 year high of $40.71.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The firm had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. During the same quarter in the prior year, the firm earned $0.10 EPS. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. As a group, analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current year.

Analysts Set New Price Targets

IMCR has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Monday, April 20th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Finally, Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $56.71.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.